PT  - JOURNAL ARTICLE
AU  - A. Ph. Makar
AU  - R. Holm
AU  - G. B. Kristensen
AU  - J. M. Nesland
AU  - C. G. TropÉ
TI  - The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
AID  - 10.1046/j.1525-1438.1994.04030194.x
DP  - 1994 Apr 01
TA  - International Journal of Gynecologic Cancer
PG  - 194--199
VI  - 4
IP  - 3
4099  - http://ijgc.bmj.com/content/4/3/194.short
4100  - http://ijgc.bmj.com/content/4/3/194.full
SO  - Int J Gynecol Cancer1994 Apr 01; 4
AB  - The expression of c-erbB-2 oncogene has been studied in 74 formalin fixed paraffin embedded invasive epithelial ovarian malignancies using a monoclonal c-erbB-2 protein antibody. Only four (5.4%) tumors showed membrane immunostaining. FIGO stage, size of residual disease after primary surgery, histologic type and tumor grade, were identified by the log rank test as prognostic factors for survival. No difference in survival was observed between those with and without membrane staining (24 months probability of survival: 50% and 55.4% respectively). Our results did not show any adverse prognostic effect of c-erbB-2 protein expression in our patients.